Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare effects of combinations of standard and intensive treatment of glycemia and either blood pressure (BP) or lipids in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: ACCORD enrolled 10,251 type 2 diabetes patients aged 40–79 years at high risk for cardiovascular disease (CVD) events. Participants were randomly assigned to hemoglobin A1c goals of <6.0% (<42 mmol/mol; intensive glycemia) or 7.0–7.9% (53–63 mmol/mol; standard glycemia) and then randomized a second time to either 1) systolic BP goals of <120 mmHg (intensive BP) or <140 mmHg (standard BP) or 2) simvastatin plus fenofibrate (intensive lipid) or simvastatin plus placebo (standard lipid). Proportional hazards models were used to assess combinations of treatment assignments on the composite primary (deaths due to CVD, nonfatal myocardial infarction [MI], and nonfatal stroke) and secondary outcomes. RESULTS: In the BP trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [HR] 0.67; 95% CI 0.50–0.91), BP (HR 0.74; 95% CI 0.55–1.00), or both (HR 0.71; 95% CI 0.52–0.96) compared with combined standard BP and glycemia treatment. For secondary outcomes, MI was significantly reduced by intensive glycemia treatment and stroke by intensive BP treatment; most other HRs were neutral or favored intensive treatment groups. In the lipid trial, the general pattern of results showed no evidence of benefit of intensive regimens (whether single or combined) compared with combined standard lipid and glycemia treatment. The mortality HR was 1.33 (95% CI 1.02–1.74) in the standard lipid/intensive glycemia group compared with the standard lipid/standard glycemia group. CONCLUSIONS: In the ACCORD BP trial, compared with combined standard treatment, intensive BP or intensive glycemia treatment alone improved major CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor glycemia treatment produced an overall benefit, but intensive glycemia treatment increased mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, SBP >140 mmHg or <120 mmHg were related to higher risk of adverse renal outcomes in patients with diabetes when compared with those without diabetes and with high CV risk.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“The Steno-2 study showed a major reduction in CVD events and mortality with multifactorial intensive treatment (5,6).”
BackgroundStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“and dysglycemia, high blood pressure (BP), and dyslipidemia mediate much of this increased CVD risk (1).”
BackgroundEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465 · cited 1×
“The Steno-2 study showed a major reduction in CVD events and mortality with multifactorial intensive treatment (5,6).”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cited by
Items 201–263 of 263
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 2
Pervyshin, N. A., Викторовна, Б. С., Galkin, R. A., Lebedev, P. A., & Долгих, Ю. А. (2025) · Успехи геронтологии · doi:10.34922/ae.2025.38.1.011 · Cited by 1
Galvañ, V. G., García, F. J. S., Navarro, D. V., & Giner, M. J. E. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.02.012 · Cited by 1
Is lower still better? Reflections on Systolic Blood Pressure Intervention Trial study
Galvañ, V. G., Sanz-García, F. J., Navarro, D. V., & Giner, M. J. E. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.02.062 · Cited by 1
Blood pressure goals in T2DM — time for a rethink?
Dojki, F. K., & Bakris, G. L. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.163 · Cited by 1
Personalised blood pressure ranges in type 2 diabetes?
Rutter, M. K., & Sattar, N. A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30002-0 · Cited by 1
Hypertension and Chronic Kidney Disease
Sternlicht, H., & Bakris, G. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00033-0 · Cited by 1
Majewski, C., & Bakris, G. L. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_5-2 · Cited by 1
Saely, C. H., Schernthaner, G.-H., Brix, J. M., Klauser‐Braun, R., Zitt, E., Drexel, H., & Schernthaner, G. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02189-1 · Cited by 1
Role of ACE Inhibitors and Angiotensin Receptor Blockers in Peripheral Artery Disease
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7380-0_8 · Cited by 1
Wang, X., Pei, J., Zheng, K., Liu, M., & Hu, X. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16112 · Cited by 1
What should the blood pressure treatment goal be in adults with hypertension in 2016?
Aronow, W. S. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.12.13 · Cited by 1
Patient-centered blood pressure: Thresholds, targets, and tools in diabetes
Kalra, S., Kishor, K., & Gupta, Y. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_37_17 · Cited by 1
Risk–benefit profile of intensive blood pressure treatment
Neves, J. S., Leitão, L., Magriço, R., Dias, C. V., & Vieira, M. B. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30175-x · Cited by 1
Du, C. X., Huang, C., Lu, Y., Spatz, E. S., Lipska, K. J., & Krumholz, H. M. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.07.023 · Cited by 1
What should the systolic blood pressure be in older diabetics treated for hypertension?
Aronow, W. S. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000079
PURLs: "Go low" or say "No" to aggressive systolic BP goals?
Day, M. A., & Stevermer, J. (2016) · PubMed
Hiremath, S., & Lokikere, S. (2016) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20162439
Diabetes und Hypertonie: Teufel und Beelzebub
Kistner, I., & Schmieder, R. E. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0115-4
Description of a disease management model in patients undergoing dialysis in Colombia
Bunch, A., Tamer, L., Ardila, F., Laganis, S., Castaño, R., Vesga, J. I., López, P., & Sanabria, M. (2016) · Revista Colombiana de Nefrología · doi:10.22265/acnef.3.1.206
Hypertension in Ischemic Heart Disease
Smith, S. M., & Pepine, C. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00031-7
Systolic blood pressure target: Have we identified the optimal target yet?
Elgendy, I. Y., & Pepine, C. J. (2017) · Journal of Public Health and Emergency · doi:10.21037/jphe.2017.06.04
Dhaybi, O. A., & Bakris, G. L. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13242
Majewski, C., & Bakris, G. L. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_5-1
Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events
Bakris, G. L., & Polonsky, T. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.016
Using Thiazides when Hypertension is Coupled with Immunoglobulin Deficiency
Lundin, M. S. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.07.001549
Management of Hypertension in Diabetes Mellitus
Doumas, M. N., & Bakris, G. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-92946-0_7
Arterielle Hypertonie bei Menschen mit Diabetes
Zidek, W. (2019) · Der Diabetologe · doi:10.1007/s11428-018-0431-y
Cardiovascular primary prevention – directed approach for individual features
Mano, T. B., Rosa, S. A., Rio, P., Timóteo, A. T., & Ferreira, R. C. (2019) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2019.07.022
O’Connor, P. J., Sperl‐Hillen, J. M., & Gilmer, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_22
Self-citationArterielle Hypertonie bei Menschen mit Diabetes
Zidek, W. (2019) · Der Kardiologe · doi:10.1007/s12181-019-0342-1
Guo, J. S. (2019) · D-Scholarship@Pitt (University of Pittsburgh)
Kardiovaszkuláris prevenció diabetes mellitusban
Vértes, A. (2020) · Diabetologia Hungarica · doi:10.24121/dh.2020.1
El manejo de la presión arterial en la era post-SPRINT
Colantonio, L. D., & Burrone, M. S. (2016) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v18i4.6402
Majewski, C., & Bakris, G. L. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_5
Majewski, C., & Bakris, G. L. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_5
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Agarwalla, A., Gruen, J., Peters, C. J., Sinnenberg, L. E., OWENS, A. T., & Reza, N. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.31
Mota, D. M. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.98.2021.tde-23022022-142032 · Cited by 1
Kowalewski, T. (2016) · Arterial Hypertension · doi:10.5603/ah.2016.0013
Pai, R. G., Varadarajan, P., & Pai, S. M. (2018) · Cardiology board review · doi:10.1002/9781118698983.ch13
Chong, S. M. Y., Hung, R. K. Y., & White, W. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_45
Secondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Ramdas G. Pai MD, F. (., & Varadarajan, P. (2023) · Wiley eBooks · doi:10.1002/9781119814979.ch14
Ramdas G. Pai MD, F. (., & Varadarajan, P. (2023) · Cardiology board review · doi:10.1002/9781119814979.ch13
Hypertension and the metabolic syndrome: toward personalized management
Neeland, I. J., & Dobre, M. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00019-x
O’Connor, P. J., Vickery, K. D., & Gilmer, T. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_24
Self-citationHipertensión arterial en la mujer
Miguel, A. M. (2023) · Anales de la Real Academia de Medicina y Cirugía de Valladolid · doi:10.24197/aramcv.56.2020.270-301
Actualización en factores de riesgo cardiovascular y diabetes mellitus
Lachica, L. Á., & García, M. D. C. G. (2024) · Diabetes práctica · doi:10.52102/diabet/pract.2024.2.art1
Pervyshin, N. A. (2024) · Успехи геронтологии · doi:10.34922/ae.2024.37.5.008
Duarte, F. G., Rocha, K. O., Magalhães, L. V. B., de Carvalho, C. J., & Lima, L. M. (2025) · Arquivos Catarinenses de Medicina · doi:10.63845/47vam533
Frazier, C. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch20
Adeyemi, O. J., Christina, W., Arcila‐Mesa, M., Dickson, V. V., Ferris, R. E., Tarpey, T., Fletcher, J., Blaum, C. S., & Chodosh, J. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108165
Kim, H.-L., Kim, H. M., Kwon, C. H., Shin, J., Jung, M.-H., Lee, C. J., Kim, D.-H., Kim, W.-H., Kang, S.-H., Lee, J.-H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13115009
The Lived Experience of Homeless Individuals with Type 2 Diabetes Mellitus
Hamilton, D. (2023) · EngagedScholarship @ Cleveland State University (Cleveland State University)
AlAlsayyad, A. S., Matar, E., Zabar, Z., Isa, A. S., Ali, M., Ali, Z. J., & Nooh, F. A. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_748_25
Niakan, A., Cushman, W. C., & Kotsis, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00369-1
Self-citationPrevention of ischaemic stroke
Patel, A. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261419691
Blood Pressure Control and Mortality Among US Veterans
Yamada, M., Griffin, B. R., Shi, Q., Sambharia, M., Swee, M. L., Good, M. K., Kennelty, K. A., Faro, E. Z., Reisinger, H. S., Girotra, S. R., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.25787
Saely, C. H., Schernthaner, G.-H., Brix, J. M., Klauser‐Braun, R., Zitt, E., Drexel, H., & Schernthaner, G. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02719-7
Preeclampsia and Hypertension in Pregnancy in Women Living with CKD
Torreggiani, M., Attini, R., Schwotzer, N., Longhitano, E., & Piccoli, G. B. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_9
Mengel, F. (2024) · Qucosa (Saxon State and University Library Dresden)
Metadata
- Authors
- Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., Lipkin, E. W., Narayan, K. M. V., Riddle, M. C., Sood, A., & Goff, D. C.
- Affiliations
- HealthPartners (US)
- Wake Forest University Health Sciences (US)
- University of North Carolina at Chapel Hill (US)
- Cincinnati VA Medical Center (US)
- Memphis VA Medical Center (US)
- National Heart, Lung, and Blood Institute (US)
- McMaster University (CA)
- Berman Center for Outcomes and Clinical Research (US)
- University of Washington (US)
- Emory University (US)
- Oregon Health & Science University (US)
- Louis Stokes Cleveland VA Medical Center (US)
- Colorado School of Public Health (US)
- Corresponding author
- Margolis, Karen L.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-05-10
- Volume
- 37
- Issue
- 6
- Pages
- 1721-1728
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4030092
- OpenAlex
- W2167872811
- Cited by
- 259
- References
- 29
- Citations by year
- 2026: 5 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 12 · 2021: 18 · 2020: 19 · 2019: 31 · 2018: 54 · 2017: 32 · 2016: 39 · 2015: 7 · 2014: 5
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Heart, Lung, and Blood Institute (N01- HC-95181, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- type 2 diabetes, cardiovascular risk management, tight glycemic control, HbA1c, blood pressure control, lipid-lowering therapy, simvastatin, fenofibrate, cardiovascular outcomes, myocardial infarction, stroke, mortality, ACCORD trial, combination therapy, cardiovascular risk reduction, high-risk patients, secondary prevention, primary prevention, cardiovascular risk stratification
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Myocardial Infarction, Outcome and Process Assessment, Health Care, Fenofibrate, Risk Factors, Disease Management, Simvastatin, Stroke, Risk Reduction Behavior, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.